Cooper Companies ( (COO) ) has released its Q2 earnings. Here is a breakdown of the information Cooper Companies presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CooperCompanies, a prominent player in the global medical device industry, specializes in contact lenses and women’s healthcare products through its CooperVision and CooperSurgical divisions. In its latest earnings report for the second quarter of 2025, CooperCompanies reported a 6% year-over-year increase in revenue, reaching $1,002.3 million. The company’s non-GAAP diluted earnings per share rose by 14% to $0.96, reflecting strong performance in its daily silicone hydrogel and surgical portfolios. Key financial metrics showed an improvement in gross and operating margins, with the latter increasing to 18% from 17% in the previous year. CooperVision’s revenue grew by 5%, while CooperSurgical saw an 8% rise, driven by robust sales in office and surgical products. Looking ahead, CooperCompanies remains focused on expanding its market share and launching new products, with a positive outlook for the remainder of the fiscal year.